U.S. markets open in 5 hours 18 minutes
  • S&P Futures

    3,886.25
    -36.50 (-0.93%)
     
  • Dow Futures

    31,185.00
    -255.00 (-0.81%)
     
  • Nasdaq Futures

    11,799.00
    -136.50 (-1.14%)
     
  • Russell 2000 Futures

    1,758.80
    -14.00 (-0.79%)
     
  • Crude Oil

    109.63
    +0.04 (+0.04%)
     
  • Gold

    1,811.40
    -4.50 (-0.25%)
     
  • Silver

    21.40
    -0.14 (-0.64%)
     
  • EUR/USD

    1.0490
    +0.0024 (+0.23%)
     
  • 10-Yr Bond

    2.8860
    0.0000 (0.00%)
     
  • Vix

    31.87
    +5.77 (+22.11%)
     
  • GBP/USD

    1.2379
    +0.0037 (+0.30%)
     
  • USD/JPY

    128.1050
    -0.1920 (-0.15%)
     
  • BTC-USD

    29,103.33
    -763.49 (-2.56%)
     
  • CMC Crypto 200

    648.01
    -22.67 (-3.38%)
     
  • FTSE 100

    7,311.38
    -126.71 (-1.70%)
     
  • Nikkei 225

    26,402.84
    -508.36 (-1.89%)
     

Zynerba Stock Moves Higher On Long-Term Zygel Data In Autistic Children

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) presented data from the Phase 2 BRIGHT trial of Zygel in children and adolescents with autism spectrum disorder (ASD) over a longer-term, 38-week treatment period.

  • Zygel is cannabidiol formulated in a transdermal gel.

  • The data were presented at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021.

  • The open-label Phase 2 study demonstrated over 35% improvement in the Aberrant Behavior Checklist-Community (ABC-C) irritability subscale at week 14. Patients were allowed to continue treatment for an additional 24 weeks.

  • In the 18 patients who completed treatment through additional 24 weeks, Zygel improved ABC-C subscale scores (51% to 61% across domains).

  • Improvements in the Parent-Rated Anxiety Scale-ASD score (42%), Autism Parenting Stress Index (40%), and the Autism Impact Measure (19% to 36% across domains) were observed, relative to baseline.

  • Zygel was generally well-tolerated, and the safety profile was consistent with data from previous Zygel clinical trials.

  • Price Action: ZYNE stock is up 4.63% at $4.52 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.